The "Immunology Drugs Market Report Suite for the United States - 2018-2024" report has been added to ResearchAndMarkets.com's offering.
The United States immunology drugs report provides market analysis, sizing, forecasts, dosage units sold, average selling prices, and market shares of the immunology drugs within 5 major diseases.
The report analyses key factors instrumental in changing the market scenario and provides a forecast of the future immunology market in the United States. Key market players are profiled and a detailed view of their current strategic interests and a review on their financial performance has been provided.
The U.S. immunology market includes biologic drugs that are used in the treatment of various immunology diseases, such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn`s disease (CD), ulcerative colitis (UC) and psoriasis (PsO). As there is a need for cost-effective drugs in treating these diseases, there is also an increased number of drugs in development for the same. Current treatment mainly constitutes NSAIDs and biologics. However, this report is limited to biologics, as they constitute 90% of the revenue in immunology. This report covers second-line treatments, their dosage, comparative cost studies, market size and revenue forecasts.
Key Topics Covered:
1 Executive Summary
- Market Overview
- Competitive Landscape
- Market Trends
- Key Market Developments
- Markets Included
- Version History
- 9-Step Methodology
2 Mechanism Of Action
2.1 Introduction
2.1.1 Tumor Necrosis Factor (Tnf)
2.1.2 B-Cell Inhibitors
2.1.3 Interleukin Inhibitors
2.1.4 Janus Kinase Inhibitors
2.1.5 Co-Stimulation Modulators
3 Product Assessment
3.1 Key Marketed Products
3.1.1 Abatacept (Orencia)
3.1.1.1 Future Developments
3.1.1.2 Currently Marketed Products By Company
3.1.2 Adalimumab (Humira)
3.1.3 Certolizumab Pegol (Cimzia)
3.1.4 Etanercept (Enbrel, Benepali)
3.1.5 Golimumab (Simponi)
3.1.6 Infliximab (Remicade, Inflectra, Remsima, Flixabi, Renflexis)
3.1.7 Natalizumab (Tysabri)
3.1.8 Rituximab (Rituxan, Mabthera, Rixathon, Truxima)
3.1.9 Tocilizumab (Actemra/Roactemra)
3.1.10 Tofacitinib (Xeljanz)
3.1.11 Ustekinumab (Stelara)
3.1.12 Vedolizumab (Entyvio)
3.2 Key Products In Pipeline
3.2.1 Barcitinb (Olumiant)
3.2.2 Guselkumab (Tremfya)
3.2.3 Cobitolimod (Kappaproct)
3.2.4 Mavrilimumab
3.2.5 Sirukumab
3.2.6 Vobarilizumab
3.3 Products In Development By Core Companies
3.4 Clinical Trial By Disease
3.4.1 Rheumatoid Arthritis
3.4.1.1 Study Completion Date: 2017
3.4.1.2 Study Completion Date: 2016 803.4.2 Crohn's Disease (Cd)
3.4.2.1 Study Completion Date: 2017
3.4.2.2 Study Completion Date: 2016
3.4.2.3 Study Completion Date: 2015
3.4.3 Ankylosing Spondylitis (As)
3.4.3.1 Study Completion Date: 2017
3.4.3.2 Study Completion Date: 2016
3.4.3.3 Study Completion Date: 2015
3.4.4 Psoriasis (Ps)
3.4.4.1 Study Completion Date: 2017
3.4.4.2 Study Completion Date: 2016
3.4.5 Ulcerative Colitis (Uc)
3.4.5.1 Study Completion Date: 2016
3.4.5.2 Study Completion Date: 2015
4 United States Immunology Market Overview
4.1 Introduction
4.2 Market Overview
4.3 Market Share Analysis
4.4 Drivers And Limiters
4.4.1 Market Drivers
4.4.2 Market Limiters
4.5 Competitive Analysis
5 Country Profile
5.1 United States
5.1.1 Population And Demographics
5.1.2 Prevalence Of Immunology Diseases
5.1.3 Drug Cost Analysis
5.1.4 Annual Drug Cost Analysis
5.1.5 Disease Treatment Population Size
5.1.6 Units Of Drugs Sold
6 Rheumatoid Arthritis Market
6.1 Introduction
6.1.1 Causes And Disease Progression
6.1.2 Diagnosis And Treatment Options
6.1.3 Symptoms And Complications
6.1.4 Epidemiology
6.2 Market Overview
6.3 Market Share Analysis
7 Crohn's Disease Market
7.1 Introduction
7.1.1 Causes And Disease Progression
7.1.2 Diagnosis And Treatment Options
7.1.3 Symptoms And Complications
7.1.4 Epidemiology
7.2 Market Overview
7.3 Trend Analysis
8 Ankylosing Spondylitis Market
8.1 Introduction
8.1.1 Causes And Disease Progression
8.1.2 Diagnosis And Treatment Options
8.1.3 Symptoms And Complications
8.1.4 Epidemiology
8.2 Market Overview
8.3 Trend Analysis
9 Psoriasis Market
9.1 Introduction
9.1.1 Causes And Disease Progression
9.1.2 Diagnosis And Treatment Options
9.1.3 Symptoms And Complications
9.1.4 Epidemiology
9.2 Market Overview
9.3 Trend Analysis
10 Ulcerative Colitis Market
10.1 Introduction
10.1.1 Causes And Disease Progression
10.1.2 Diagnosis And Treatment Options
10.1.3 Symptoms And Complications
10.1.4 Epidemiology
10.2 Market Overview
10.3 Trend Analysis
11 Company Profiles
11.1 Abbvie Inc.
11.1.1 Business Overview
11.1.2 Financials
11.1.3 Swot Analysis
11.1.3.1 Strengths
11.1.3.2 Weakness
11.1.3.3 Opportunity
11.1.3.4 Threats
11.2 Amgen Inc.
11.3 Biogen Idec
11.4 Bristol-Myers Squibb
11.5 Hoffmann-La Roche Ltd
11.6 Johnson & Johnson/Janssen
11.7 Novartis Ag
11.8 Pfizer Inc.
11.9 Takeda Pharmaceutical Company Limited
11.10 Ucb S.A.
12 Abbreviations
13 Appendix: Company Press Releases
For more information about this report visit https://www.researchandmarkets.com/research/n5d49s/united_states?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20190227005319/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
